Takahashi et al. demonstrated that RPN2 antagonizes GSK-3β through physical interaction leading to inactivation of GSK-3β phosphorylation and subsequently enhancement of mtp53 stabilization to promote the tumor initiation, metastasis, and cancer stem cell (CSC) property acquisition in breast cancer15. The gene discussed is RPN2; the disease is neoplasm.